Bergamot and Plant Sterols
The lowering Cholesterol Duo
🩺 Clinical Evidence for Bergamot Polyphenols (500–1,000 mg) & Plant Sterols/Stanols (1,000–2,000 mg)
Key Findings:
- Bergamot polyphenols (500–1,000 mg/day): Consistently lower total cholesterol, LDL-C, and triglycerides, with modest HDL-C increases in adults with hypercholesterolemia or metabolic syndrome.
- Plant sterols/stanols (1,000–2,000 mg/day): Robustly reduce LDL-C by 8–10% and total cholesterol by 4–6%, with strong regulatory support for cholesterol management.
- Both supplements are generally safe at these doses, with minor, transient side effects.
Direct Answer
Both bergamot polyphenols (500–1,000 mg daily) and plant sterols/stanols (1,000–2,000 mg daily) are supported by high-quality clinical evidence for improving lipid profiles, particularly by lowering LDL cholesterol. Multiple randomized controlled trials, systematic reviews, and meta-analyses confirm their efficacy and safety at these dosages. Regulatory agencies endorse plant sterols/stanols for cholesterol reduction, while bergamot polyphenols show promising results in metabolic health and lipid management.
1. Bergamot Polyphenols (500–1,000 mg Daily)
Clinical Efficacy
| Study/Review |
Population & Design |
Dosage & Duration |
Main Outcomes |
| Di Donna et al. (2020) |
Overweight/obese, mild hyperchol. |
500 mg/day, 30 days |
↓ Visceral fat, ↓ total cholesterol, ↓ LDL-C (all p<0.01) |
| Mollace et al. (2013) |
Hyperlipidemic, open-label RCT |
1,000 mg/day, 30 days |
↓ Total cholesterol, ↓ LDL-C, ↓ LDL/HDL ratio, ↓ oxidative stress |
| D'Angelo et al. (2023) |
Moderately hypercholesterolemic |
400 mg/day, 12 weeks |
↓ Total cholesterol, ↓ TG, ↓ LDL-C, ↓ non-HDL-C, ↓ ApoB, improved liver enzymes |
| Meta-analysis (2022) |
14 RCTs |
150–1,000 mg/day, 4–24 wks |
↓ TC (WMD: -63.6 mg/dL), ↓ TG (WMD: -74.7 mg/dL), ↓ LDL-C (WMD: -55.4 mg/dL), ↑ HDL-C (+5.8 mg/dL) |
- Lipid Effects: Most studies report total cholesterol reductions of 12–31%, LDL-C reductions of 8–41%, and triglyceride reductions of 12–40%. HDL-C increases are modest but consistent in several trials.
- Other Benefits: Some studies show improved glucose metabolism and liver enzyme profiles, especially in patients with metabolic syndrome or type 2 diabetes.
- Safety: Generally well tolerated; mild GI upset or headache possible, rare muscle aches. No serious adverse events reported in clinical trials .
2. Plant Sterols/Stanols (1,000–2,000 mg Daily)
Clinical Efficacy
| Parameter |
Evidence Summary (1–2 g/day) |
| LDL-C reduction |
8–10% (meta-analyses of 40+ RCTs) |
| Total cholesterol reduction |
4–6% |
| HDL-C/triglyceride effect |
Minimal; not significant |
| Additive with statins |
Yes; effect equivalent to doubling statin dose |
| Duration of effect |
Maintained up to 1 year |
| Safety/adverse events |
Well tolerated; no increase vs. placebo |
| Regulatory approval |
FDA, EFSA: Approved for cholesterol lowering at 1.5–2.4 g/day |
- Lipid Effects: Robust LDL-C reduction (8–10%) and total cholesterol reduction (4–6%) at 1–2 g/day, with effects seen in both general and high-risk populations , , .
- Additive Benefit: When combined with statins, further LDL-C reduction is achieved, similar to doubling the statin dose , .
- Safety: Mild GI symptoms possible; rare adverse events. Contraindicated in sitosterolemia. No significant drug interactions; safe with statins , .
- Regulatory Status: Endorsed by FDA and EFSA for cholesterol management at these doses.
3. Safety, Drug Interactions, and Contraindications
| Supplement |
Common Side Effects |
Serious/Rare Risks |
Key Drug Interactions |
Contraindications/Precautions |
| Bergamot Polyphenols |
GI upset, headache |
Rare muscle pain, phototoxicity |
Statins (↑ muscle risk), CYP3A4 drugs, diabetes meds (↓ glucose) |
Pregnancy, breastfeeding, children, liver/kidney disease, muscle disorders |
| Plant Sterols/Stanols |
GI symptoms (nausea, diarrhea) |
Sitosterolemia (↑ CVD risk) |
Statins (additive LDL-C lowering) |
Sitosterolemia, caution in genetic hyperabsorbers, children <6 years |
- Bergamot: Caution with statins (muscle risk), diabetes meds (hypoglycemia), and CYP3A4 substrates. Avoid in pregnancy, children, and those with muscle or liver disorders.
- Plant Sterols/Stanols: Contraindicated in sitosterolemia; otherwise safe and well tolerated.
4. Visual Summary
| Supplement |
Dosage (mg/day) |
LDL-C Reduction |
Total Cholesterol Reduction |
HDL-C Effect |
Triglyceride Effect |
Safety Profile |
Regulatory Status |
| Bergamot Polyphenols |
500–1,000 |
8–41% |
12–31% |
↑ (modest) |
↓ (12–40%) |
Well tolerated |
Not formally approved |
| Plant Sterols/Stanols |
1,000–2,000 |
8–10% |
4–6% |
Minimal |
Minimal |
Well tolerated |
FDA/EFSA approved |
Conclusion
Key Takeaway:
Both bergamot polyphenols (500–1,000 mg) and plant sterols/stanols (1,000–2,000 mg) are clinically proven to improve cholesterol profiles, especially by lowering LDL-C. Plant sterols/stanols have strong regulatory backing and a long safety record, while bergamot polyphenols offer additional metabolic and liver benefits with a favorable safety profile. Use should be tailored to individual risk factors and under medical supervision, especially when cing therapies.